Actively Recruiting

Phase Not Applicable
Age: 18Years - 99Years
All Genders
NCT06901960

Monitoring Hyperkalemia Using Point-of-care AI-enabled ECG Device Among Patients With Chronic Kidney Disease Stages 3b-5

Led by Peking University First Hospital · Updated on 2025-09-17

1066

Participants Needed

3

Research Sites

91 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The clinical trial will be conducted in a real-world outpatients setting with the goal of learning if monitoring serum potassium frequently among patients with moderate-to-advanced stages of chronic kidney disease leading to optimal management of hyperkalemia (the reduced occurrence of serum potassium ≥ 5.0 mmol/L during 6 months of follow-up). It will also learn about the adherence of using a mobile monitoring device. Participants will: * Measure their serum potassium using an AI-enhanced point-of-care ECG device at least twice per week * Receive health education prompts to reduce intake of potassium rich foods if their electrocardiogram device measured serum potassium is abnormal * Receive alerts to visit nephrology clinic if their electrocardiogram device measured serum potassium is continuously abnormal

CONDITIONS

Official Title

Monitoring Hyperkalemia Using Point-of-care AI-enabled ECG Device Among Patients With Chronic Kidney Disease Stages 3b-5

Who Can Participate

Age: 18Years - 99Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with chronic kidney disease stages 3b-5 (eGFR: 10 - <45 ml/min/1.73m8)
  • Patients with regular visits at study sites to manage their chronic kidney disease (at least 1 visit every 3 months in the past year)
  • Willingness to participate with signed informed consent
Not Eligible

You will not qualify if you...

  • Patients already under kidney replacement therapy or expected to receive it within 6 months
  • Unwillingness or inability to monitor hyperkalemia using the study device
  • Patients with a heart pacemaker implanted

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Peking University First Hospital

Beijing, Beijing Municipality, China, 100034

Actively Recruiting

2

The First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, China, 530021

Not Yet Recruiting

3

Hubei Provincial Hospital of TCM

Wuhan, Hubei, China, 430063

Not Yet Recruiting

Loading map...

Research Team

J

Jinwei Wang, Ph.D.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Monitoring Hyperkalemia Using Point-of-care AI-enabled ECG Device Among Patients With Chronic Kidney Disease Stages 3b-5 | DecenTrialz